PTPRC and renal cell carcinoma: We pooled CD45+ sorted (Supplementary Fig. 2a, b), scRNA+TCRαβ profiled blood samples from patients with CML (diagnosis n = 4 [6], TKI induced remission n = 6, TKI discontinuation n = 6, N = 10), and untreated renal cell carcinoma (RCC, n = 3) [20], non-small cell lung carcinoma (NSCLC, n = 1) [20], acute myeloid leukemia (AML, n = 11) [23], chronic lymphocytic leukemia (CLL, n = 13) [21, 24], and healthy controls (n = 7) [25, 26] (Fig. 1a, Supplementary Table 1).